This afternoon we watched Sarepta Therapeutics rise 5.6% to a price of $58.34 per share. The Mid-Cap Pharmaceutical company is now trading -60.85% below its average target price of $149.0. Analysts have set target prices ranging from $70.0 to $209.0 per share for Sarepta Therapeutics, and have given the stock an average rating of buy.
The stock has an average amount of shares sold short at 6.6%, and a short ratio of 2.68. Since 4.42% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 92.9% of Sarepta Therapeutics's shares being owned by this investor type.
Institutions Invested in Sarepta Therapeutics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-12-31 | Blackrock Inc. | 12% | 11,191,986 | $652,902,424 |
| 2024-12-31 | Vanguard Group Inc | 9% | 9,085,456 | $530,014,623 |
| 2024-12-31 | Capital International Investors | 9% | 8,697,137 | $507,361,413 |
| 2024-12-31 | Janus Henderson Group PLC | 4% | 4,328,323 | $252,499,652 |
| 2024-12-31 | State Street Corporation | 4% | 4,069,864 | $237,422,033 |
| 2024-12-31 | Farallon Capital Management LLC | 3% | 2,865,100 | $167,140,196 |
| 2024-12-31 | Avoro Capital Advisors LLC | 3% | 2,555,555 | $149,082,393 |
| 2024-12-31 | Bank Of New York Mellon Corporation | 2% | 2,145,484 | $125,160,244 |
| 2024-12-31 | Wellington Management Group, LLP | 2% | 2,068,771 | $120,685,068 |
| 2024-12-31 | JPMORGAN CHASE & CO | 2% | 2,020,604 | $117,875,169 |
Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Sarepta Therapeutics.
